HDACi have shown promising results against a myriad of neurological disorders including AD, HD, PD, SMA, ALS and epilepsy. It is quite evident that in a particular neurological complication, neuronal death or damage is not general, but specific brain regions are particularly affected. Different focal pathologies are exhibited by distinct disorders, and thus gaining insights regarding the region-specific effects of these inhibitors is requisite for targetting correct brain areas. This will subsequently mitigate the toxicity in the normal brain regions.
- Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA (2013) Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 9(5):319–325CrossRefGoogle Scholar